Bradykinin Pathway

How it works

Benefits

Highlighted claims

• KLK1 cleaves kininogen to release bradykinin. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
• Bradykinin binds the B2 receptor on endothelial cells and upregulates nitric oxide, prostacyclin, and endothelium-derived hyperpolarising factor. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
• The vasodilator molecules induced by bradykinin signalling relax vascular smooth muscle, producing vasodilation and blood pressure reduction. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
• Bradykinin/B2 receptor signalling may bypass the sFlt-1 block central to pre-eclampsia pathogenesis by restoring VEGFR2 activity. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
• B2 receptor activation may reduce inflammation, increase antioxidant defenses, and improve insulin sensitivity. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial